UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Annals of oncology, 2020-07, Vol.31 (7), p.942-950

2020

Volltextzugriff (PDF)

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Annals of oncology, 2022-04, Vol.33 (4), p.406-415

2022

Volltextzugriff (PDF)

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

Annals of oncology, 2018-08, Vol.29 (8), p.1807-1813

2018

Volltextzugriff (PDF)

Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor

Annals of oncology, 2015-02, Vol.26 (2), p.348-354

2015

Volltextzugriff (PDF)

Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma

Annals of oncology, 2017-04, Vol.28 (4), p.890-897

2017

Volltextzugriff (PDF)

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

Annals of oncology, 2017-02, Vol.28 (2), p.292-297

2017

Volltextzugriff (PDF)

Low albumin-to-globulin ratio associated with cancer incidence and mortality in generally healthy adults

Annals of oncology, 2014-11, Vol.25 (11), p.2260-2266

2014

Volltextzugriff (PDF)

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Annals of oncology, 2017-11, Vol.28 (11), p.2754-2760

2017

Volltextzugriff (PDF)

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

Annals of oncology, 2013-08, Vol.24 (8), p.2080-2087

2013

Volltextzugriff (PDF)

A noninferiority trial of cabozantinib (C) comparing 60mg vs 140mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)

Annals of oncology, 2018-10, Vol.29, p.viii647-viii648

2018

Volltextzugriff (PDF)

Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

ESMO open, 2021-12, Vol.6 (6), p.100309, Article 100309

2021

Volltextzugriff (PDF)

Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors

Annals of oncology, 2018-10, Vol.29, p.viii410-viii410

2018

Volltextzugriff (PDF)

Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study

ESMO open, 2023-04, Vol.8 (2), p.100877-100877, Article 100877

2023

Volltextzugriff (PDF)

Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)

Annals of oncology, 2018-10, Vol.29, p.viii645-viii646

2018

Volltextzugriff (PDF)

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

ESMO open, 2024-08, Vol.9 (8), p.103643, Article 103643

2024

Volltextzugriff (PDF)

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18

ESMO open, 2023-08, Vol.8 (4), p.101588, Article 101588

2023

Volltextzugriff (PDF)

Acquired resistance mechanisms to INC280, a MET inhibitor in MET-amplified lung cancer cells

European journal of cancer (1990), 2016-12, Vol.69, p.S135-S136

2016

Volltextzugriff (PDF)

Implication of Tumor Location on Lymph Node Metastasis in Carcinoma of Maxillary Sinus: Indication for Elective Nodal Treatment

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.E376-E376

2016

Volltextzugriff (PDF)

2866 Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012

European journal of cancer (1990), 2015-09, Vol.51, p.S579-S579

2015

Volltextzugriff (PDF)

153 Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.47-47

2012

Volltextzugriff (PDF)

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

The New England journal of medicine, 2015-11, Vol.373 (19), p.1814-1823

2015

Volltextzugriff (PDF)

Dose-Volume Predictors of Late Dysphagia after Definitive Radiotherapy in Larynx and Pharynx Cancer

International journal of radiation oncology, biology, physics, 2024-10, Vol.120 (2), p.e793-e794

2024

Volltextzugriff (PDF)

EP07.03-001 Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S330

2022

Volltextzugriff (PDF)

Seaweed processing using industrial single-mode cavity microwave heating: a preliminary investigation

Carbohydrate research, 2005-05, Vol.340 (7), p.1357-1364

2005

Volltextzugriff (PDF)

1491P PD-L1 TPS ≥50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients

Annals of oncology, 2023-10, Vol.34, p.S841-S842

2023

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(147)
Mit Volltextzugriff
(142)

Publikationsform

Artikel
(154)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(41)
Humans
(29)
Oncology
(22)
Male
(18)
Female
(14)
Middle Aged
(13)
Adult
(11)
Aged
(11)
Hematology, Oncology And Palliative Medicine
(11)
Engineering
(10)
Engineering, Electrical & Electronic
(10)
Technology
(10)
Tumors
(10)
Cancer
(9)
Aged, 80 And Over
(8)
Applied Sciences
(8)
Electronics
(8)
Exact Sciences And Technology
(8)
Mutation
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study

Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor

Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

Low albumin-to-globulin ratio associated with cancer incidence and mortality in generally healthy adults

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

A noninferiority trial of cabozantinib (C) comparing 60mg vs 140mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC)

Pan-Asian adaptation of the EHNS–ESMO–ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck

Safety and clinical activity of MEDI0562, a humanized OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors

Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study

Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E–mutated anaplastic thyroid cancer (ATC)

A phase I trial of LHC165 single agent and in combination with spartalizumab in patients with advanced solid malignancies

Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18

Acquired resistance mechanisms to INC280, a MET inhibitor in MET-amplified lung cancer cells

Implication of Tumor Location on Lymph Node Metastasis in Carcinoma of Maxillary Sinus: Indication for Elective Nodal Treatment

2866 Antitumor activity of the Anti-PD-1 antibody pembrolizumab in subgroups of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): Exploratory analyses from KEYNOTE-012

153 Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

Dose-Volume Predictors of Late Dysphagia after Definitive Radiotherapy in Larynx and Pharynx Cancer

EP07.03-001 Comparison of Treatment Outcomes in Neoadjuvant Chemotherapy and Chemo-radiotherapy for Thymoma and Thymic Carcinoma

Seaweed processing using industrial single-mode cavity microwave heating: a preliminary investigation

1491P PD-L1 TPS ≥50% predicts durable response after discontinuing immune checkpoint inhibitors in metastatic non-small cell lung cancer patients

Suchergebnisse filtern